Business Description
![Novartis AG Novartis AG logo](https://static.gurufocus.com/logos/0C00000BWJ.png?14)
Novartis AG
NAICS : 325412
ISIN : US66987V1098
Share Class Description:
STU:NOTA: ADRDescription
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.36 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | 1.47 | |||||
Interest Coverage | 12.02 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.25 | |||||
Beneish M-Score | -2.56 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 4.3 | |||||
3-Year EPS without NRI Growth Rate | 4.6 | |||||
3-Year FCF Growth Rate | 4.2 | |||||
3-Year Book Growth Rate | -3.9 | |||||
Future 3-5Y EPS without NRI Growth Rate | 9.41 | |||||
Future 3-5Y Total Revenue Growth Rate | 2.3 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.15 | |||||
9-Day RSI | 58.51 | |||||
14-Day RSI | 61.3 | |||||
6-1 Month Momentum % | 5.38 | |||||
12-1 Month Momentum % | 7.3 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.9 | |||||
Quick Ratio | 0.71 | |||||
Cash Ratio | 0.33 | |||||
Days Inventory | 181.15 | |||||
Days Sales Outstanding | 58.85 | |||||
Days Payable | 128.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.6 | |||||
Dividend Payout Ratio | 0.84 | |||||
3-Year Dividend Growth Rate | 3.8 | |||||
Forward Dividend Yield % | 3.6 | |||||
5-Year Yield-on-Cost % | 3.92 | |||||
3-Year Average Share Buyback Ratio | 3.2 | |||||
Shareholder Yield % | 8.77 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 72.79 | |||||
Operating Margin % | 21.28 | |||||
Net Margin % | 30.18 | |||||
FCF Margin % | 20.41 | |||||
ROE % | 32.69 | |||||
ROA % | 14.08 | |||||
ROIC % | 10.29 | |||||
ROC (Joel Greenblatt) % | 93.98 | |||||
ROCE % | 14.58 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 14.65 | |||||
Forward PE Ratio | 14.49 | |||||
PE Ratio without NRI | 24.08 | |||||
Shiller PE Ratio | 18.08 | |||||
Price-to-Owner-Earnings | 10.96 | |||||
PS Ratio | 4.41 | |||||
PB Ratio | 5.46 | |||||
Price-to-Free-Cash-Flow | 21.64 | |||||
Price-to-Operating-Cash-Flow | 15.96 | |||||
EV-to-EBIT | 21.86 | |||||
EV-to-Forward-EBIT | 15.2 | |||||
EV-to-EBITDA | 12.6 | |||||
EV-to-Forward-EBITDA | 12.18 | |||||
EV-to-Revenue | 4.69 | |||||
EV-to-Forward-Revenue | 4.72 | |||||
EV-to-FCF | 22.97 | |||||
Price-to-Projected-FCF | 1.48 | |||||
Price-to-Median-PS-Value | 1.16 | |||||
Earnings Yield (Greenblatt) % | 4.57 | |||||
FCF Yield % | 4.71 | |||||
Forward Rate of Return (Yacktman) % | 9.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novartis AG Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 46,142.124 | ||
EPS (TTM) (€) | 6.749 | ||
Beta | 0.48 | ||
Volatility % | 10.75 | ||
14-Day RSI | 61.3 | ||
14-Day ATR (€) | 1.0427 | ||
20-Day SMA (€) | 95.77 | ||
12-1 Month Momentum % | 7.3 | ||
52-Week Range (€) | 81.364424 - 100.5 | ||
Shares Outstanding (Mil) | 2,040.41 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Novartis AG Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Novartis AG Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Novartis AG Frequently Asked Questions
What is Novartis AG(STU:NOTA)'s stock price today?
The current price of STU:NOTA is €97.60. The 52 week high of STU:NOTA is €100.50 and 52 week low is €81.36.
When is next earnings date of Novartis AG(STU:NOTA)?
The next earnings date of Novartis AG(STU:NOTA) is 2024-07-18.
Does Novartis AG(STU:NOTA) pay dividends? If so, how much?
The Dividend Yield %  of Novartis AG(STU:NOTA) is 3.6% (As of Today), Highest Dividend Payout Ratio of Novartis AG(STU:NOTA) was 1.19. The lowest was 0.33. And the median was 0.85. The  Forward Dividend Yield % of Novartis AG(STU:NOTA) is 3.6%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |